Literature DB >> 21238618

IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway.

Zhaoxu Li1, Qiang Xu, Huiqin Peng, Ruilin Cheng, Zhengwang Sun, Zhaoming Ye.   

Abstract

Osteosarcoma is the second highest cause of cancer-related death in children and adolescents, partly due to dysfunction of the Fas/FasL signaling pathway, which leads to develop fatal metastasis. Since presenting no or low levels of Fas expression, resisting Fas ligand-induced apoptosis, and lack of FasL in the host environment, osteosarcoma cells always promote metastases growth and proliferate in the lungs. Therefore, agents, which up-regulate tumor cell surface Fas expression and function, in combination with immune cells, may be effective in treating osteosarcoma, especially lung metastases. The aim of this work was to investigate the effect of γδ T cells in combination with IFN-γ in treating osteosarcoma in vitro. In the present study, we found that IFN-γ up-regulated the expression of Fas in osteosarcoma cell lines, HOS and U2OS, resulting in an enhanced susceptibility of cells to γδ T cells lyses. Moreover, this cytotoxicity was prevented by treatment with FasL-blocking antibodies. These data suggest that adoptive transfer of γδ T cells in combination with IFN-γ may substantially increase anti-osteosarcoma activities and represent a novel strategy for osteosarcoma adjunct immunotherapy.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21238618     DOI: 10.1016/j.intimp.2011.01.001

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  23 in total

Review 1.  Adoptive Cell Therapy in Treating Pediatric Solid Tumors.

Authors:  Mekdem Tesfaye; Barbara Savoldo
Journal:  Curr Oncol Rep       Date:  2018-08-01       Impact factor: 5.075

2.  Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.

Authors:  Aneta Zysk; Mark O DeNichilo; Vasilios Panagopoulos; Irene Zinonos; Vasilios Liapis; Shelley Hay; Wendy Ingman; Vladimir Ponomarev; Gerald Atkins; David Findlay; Andrew Zannettino; Andreas Evdokiou
Journal:  Cancer Lett       Date:  2016-11-16       Impact factor: 8.679

Review 3.  Harnessing the power of Vδ2 cells in cancer immunotherapy.

Authors:  D W Fowler; M D Bodman-Smith
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

Review 4.  Adoptive cell therapy for sarcoma.

Authors:  Melinda Mata; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

Review 5.  The role of recipient T cells in mesenchymal stem cell-based tissue regeneration.

Authors:  Yi Liu; Songlin Wang; Songtao Shi
Journal:  Int J Biochem Cell Biol       Date:  2012-08-09       Impact factor: 5.085

6.  Vav1-phospholipase C-γ1 (Vav1-PLC-γ1) pathway initiated by T cell antigen receptor (TCRγδ) activation is required to overcome inhibition by ubiquitin ligase Cbl-b during γδT cell cytotoxicity.

Authors:  Shanshan Yin; Jianmin Zhang; Yujia Mao; Yu Hu; Lianxian Cui; Ning Kang; Wei He
Journal:  J Biol Chem       Date:  2013-07-29       Impact factor: 5.157

Review 7.  γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer.

Authors:  Bruno Silva-Santos; Sofia Mensurado; Seth B Coffelt
Journal:  Nat Rev Cancer       Date:  2019-07       Impact factor: 60.716

8.  Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α.

Authors:  Yi Liu; Lei Wang; Takashi Kikuiri; Kentaro Akiyama; Chider Chen; Xingtian Xu; Ruili Yang; Wanjun Chen; Songlin Wang; Songtao Shi
Journal:  Nat Med       Date:  2011-11-20       Impact factor: 53.440

9.  Bone sarcomas: from biology to targeted therapies.

Authors:  Nathalie Gaspar; Angela Di Giannatale; Birgit Geoerger; Françoise Redini; Nadège Corradini; Natacha Enz-Werle; Franck Tirode; Perrine Marec-Berard; Jean-Claude Gentet; Valérie Laurence; Sophie Piperno-Neumann; Odile Oberlin; Laurence Brugieres
Journal:  Sarcoma       Date:  2012-11-27

Review 10.  T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities.

Authors:  Zhan Wang; Binghao Li; Yingqing Ren; Zhaoming Ye
Journal:  Front Immunol       Date:  2016-09-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.